Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I
Eur J Haematol 2004: 73: 380–383. © Blackwell Munksgaard 2004. Abstract:
Interferon has been shown to be an effective treatment of congenital dyserythropoiesis type I (CDA-I), but the optimal dose and the feasibility of this treatment remains to be determined. Here, in a 9-yr follow-up of a single patient, we show that interferon remains active during such a long period. The optimal dose of conventional alpha interferon could be evaluated at 2 million units twice a week. Pegylated interferon could be used as well at a dose of 30 g/wk. During interferon treatment, serum and erythrocyte ferritin levels decreased progressively, and remained inversely correlated with haemoglobin levels. On repeated liver biopsies, iron overload could be normalized. Low dose interferon is a long-term treatment of CDA-I, and allows a significant decrease in iron overload, that could be interesting even in patients who are only moderately anaemic.
Document Type: Research Article
Affiliations: 1: Laboratoire d'Histologie-Embryologie-Cytogénétique, Faculté de Médecine de Montpellier-Nîmes et Laboratoire de Cytologie Clinique et Cytogénétique, C.H.U. de Nîmes 2: Laboratoire d'Anatomie Pathologique, C.H.U., Montpellier 3: Service de Médecine Nucléaire, C.H.U., Montpellier 4: Service d'Hépato-Gastro-Entérologie, C.H.U., Montpellier, France
Publication date: November 1, 2004